chrisvoncsefalvay/vaers-outcomes huggingface dataset:
5mins post vaccination pt reported that he was lightheaded, pale, and diaphoretic.  Denies CP, palp, SOB, or LOC. Vitals: 11:35 110/63, 58, 18, 98% RA -- > 11:45 125/56, 73, 98% RA -- > 11:47 128/66, 68, 20, 99% RA -- > 129/64, 61, 98% RA Pt observed an additional 20mins.  Most likely s/sx were associated w/ a vaso-vagal reaction.  After ambulation, pt denies symptoms.  Pt stable and released from the vaccination site.
Patient given GARDASIL in Lt deltoid while sitting on exam table next to mother, mother stated he fainted after immunization while nurse was out of the room. Lasted approximately 15 sec. Patient able to go home from clinic in 15 minutes.
This spontaneous report was received from a licensed practical nurse, referring to a patient of unknown age and gender. The patient's pertinent medical history, concurrent conditions, previous drug reactions, allergies, or concomitant medications were not reported. On 24-AUG-2020, the patient was vaccinated with an improperly stored varicella virus vaccine live (VARIVAX) injection, 0.5 milliliter (ml) once (lot number S032355 which has been verified to be valid, expiration date reported and validated as 14-OCT-2021) (vaccination scheme, route of administration and anatomical site of injection were not reported), as prophylaxis (product storage error). The administered dose of the vaccine was stored at a temperature of -9 degrees Celsius (C) to 8 C (-2.8 C), during a time frame of 5 hours and 2 minutes, as recorded by a digital data logger. There was no previous temperature excursion.  This is one of several reports received from the same reporter.; Sender's Comments:  US-009507513-2009USA001227: US-009507513-2009USA000677: US-009507513-2009USA001303: US-009507513-2009USA001333: US-009507513-2009USA001367: US-009507513-2009USA001381:
Treatment included dilauded, ativan, and comfort care. admitted for COVID-19, GIP Respiratory Distress and Agitation
I began feeling sick on 18JAN2023 the next morning my COVID-19 test was positive my doctor prescribed Paxlovid I began taking it and on the second dose I began to feel better on 23JAN2013 I was still positive. 24Jan2023 I was testing negative and tested negative for several days.  I had a rebound later.
Uncertain if this was the Pfizer or Moderna COVID vaccine, patient doesnt remember. He thinks he got it at pharmacy. Patient is a 79 year old man with COPD on chronic 3LPM oxygen who developed chills, myalgias and trouble breathing about 18-24 hours after his first dose of COVID vaccine. He held out for a week outside the hospital before coming in to be admitted on 1/24/2021. Found to have increased oxygen requirements to 6LPM and new bilateral left lower lobe and right lower lobe pulmonary opacities, L side worse than R. Patient is afebrile, tachypneic, and mildly tachycardic with normal blood pressure. Imaging consistent with multifocal pneumonia. Patients labs are significant for elevated white count to 13, with neutrophil predominance, normal absolute lymphocyte count. Basic metabolic panel unremarkable. Influenza A and B PCR are negative, Cepheid SARS-COV2 PCR was negative. Troponin BNP and EKG are normal. Patient was admitted to the ICU on 1/24/2021 and started on rocephin and azithromycin for community acquired pneumonia. He was also treated with duoneb inhalers and IV methylprednisolone, though it's not clear to me he was in COPD exacerbation with wheezing while he was in the ER. He is currently still only a few hours into his hospital stay and is in stable condition, though still requiring 6LPM O2 up from his baseline of 3LPM.
Patient received the powder portion of Menveo mixed with Pfizer COVID diluent.  Both the Menveo and Pfizer COVID vials have same colored top.  Pt. observed for 15mins with no adverse event and/or outcome.  Pt will be advised to return to repeat COVID vaccine.
Large red, raised spot around the injection shot. The spot was very hot to the touch and quite tender. I noticed the spot on Tuesday afternoon and by Wednesday morning it had grown larger. I also was very fatigued, had a mild fever and sore throat.
PATIENT DEVELOPED PUFFINESS OF THE EYES, A SENSATION OF "FULLNESS" IN THE FACE, THE SENSATION OF PINS AND NEEDLES IN BOTH ARMS, AND THE FEELINGS WORSEN UPON STANDING UP. A BANOPHEN 50 MG WAS ADMINISTERED ORALLY ALONG WITH A BOTTLE OF WATER AND ASKED TO WAIT LONGER IN THE LOBBY. PATIENT STATED FEELING BETTER APPROXIMATELY 10 MINUTES AFTER TAKING THE BENADRYL AND INSTRUCTED TO TAKE ANOTHER DOSE OF BENADRYL 4 TO 6 HOURS LATER IF NEEDED.
Patient returned to pharmacy 08/06/2019 displaying redness and swelling of the left arm from his shoulder to mid-forearm. He stated he was also experiencing localized itching and a sunburn-type sensation which began approximately 2 hours after the immunization. He has taken diphenhydramine for the reaction, but has not experienced much improvement.
breaking out in hives all over his body; An area on his arm or leg will begin itching terribly; Turn red; A spot on arm would turn red and begin itching; This spontaneous case was reported by a consumer and describes the occurrence of URTICARIA (breaking out in hives all over his body), PRURITUS (An area on his arm or leg will begin itching terribly), ERYTHEMA (Turn red) and RASH MACULAR (A spot on arm would turn red and begin itching) in a 68-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 020B21A and 040A21A) for COVID-19 vaccination.     Concurrent medical conditions included Kidney stones since 07-Mar-2020. Concomitant products included LYSINE for Cold sores, VITAMIN B COMPLEX for Vitamin B complex supplementation.   On 26-Mar-2021 at 10:00 AM, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 22-Apr-2021 at 10:00 AM, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 28-Apr-2021, the patient experienced URTICARIA (breaking out in hives all over his body). 28-Apr-2021, the patient experienced PRURITUS (An area on his arm or leg will begin itching terribly), ERYTHEMA (Turn red) and RASH MACULAR (A spot on arm would turn red and begin itching). The patient was treated with TRIAMCINOLONE ACETONIDE (topical) on 08-Jun-2021 for Adverse event, at an unspecified dose and frequency and HYDROXYZINE (oral) on 08-Jun-2021 for Adverse event, at an unspecified dose and frequency. On 31-Jul-2021, URTICARIA (breaking out in hives all over his body), PRURITUS (An area on his arm or leg will begin itching terribly), ERYTHEMA (Turn red) and RASH MACULAR (A spot on arm would turn red and begin itching) had resolved.            Most recent FOLLOW-UP information incorporated above includes: On 05-Aug-2021: Follow-up information received on 05-AUG-2021 contains significant information Patient demographics, Treatment drug information was added and event added and outcome of event updated, reporters causality updated.
Patient reported light headedness for a few days after the vaccine. She also reported worsening of parkinson symptoms for one week after the vaccine. Both of her doctors advised her to get the second dose.
Systemic: Allergic: Difficulty Breathing-Mild, Systemic: Allergic: Difficulty Swallowing, Throat Tightness-Mild, Systemic: Abdominal Pain-Mild, Systemic: chest pain-Mild, Systemic: Headache-Mild
just a slightly sore arm; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 77 year-old female patient received bnt162b2 (BNT162B2), administration date 20Jan2021 (Lot number: EL3246) at the age of 76 years as dose 1, single and (Lot number: EN9581) as dose 2, single for covid-19 immunisation. Relevant medical history included: "Blood pressure" (unspecified if ongoing); "allergic to dust" (unspecified if ongoing), notes: she is allergic to dust and has environmental allergies; "environmental allergies" (unspecified if ongoing). The patient took concomitant medications. The following information was reported: PAIN IN EXTREMITY (non-serious) with onset 2021, outcome "unknown", described as "just a slightly sore arm".  Additional information: Patient had a medication for Blood Pressure, but she had taken that for years and it was nothing new. she was allergic to dust and had environmental allergies.   No follow-up attempts are possible. No further information is expected.
Broke out around 3/12/01 with small bumps that appear to have a blister on them. Brother had chickenpox, 2 weeks prior. DX: Chickenpox.
Self Test: Positive/Since the vaccination, has the patient been tested for COVID-19?:Yes; Self Test: Positive/Since the vaccination, has the patient been tested for COVID-19?:Yes; I felt ill, super fatigued with a sore throat.; I felt ill, super fatigued with a sore throat.; I felt ill, super fatigued with a sore throat.; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 28-year-old male patient received BNT162b2 (BNT162B2), on 08Mar2021 as dose 1, single (Lot number: EL3247), on 30Mar2021 as dose 2, single (Lot number: EpG955) and on 11Dec2021 as dose 3 (booster), single (Lot number: 330308D) at the age of 28 years for covid-19 immunisation. The patient had no relevant medical history. There were no concomitant medications. The following information was reported: OROPHARYNGEAL PAIN (non-serious), FATIGUE (non-serious), MALAISE (non-serious) all with onset 20Jun2022, outcome "recovering" and all described as "I felt ill, super fatigued with a sore throat."; VACCINATION FAILURE (medically significant), COVID-19 (medically significant) all with onset 30Jun2022, outcome "unknown" and all described as "Self Test: Positive/Since the vaccination, has the patient been tested for COVID-19?:Yes". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 antibody test: (30Jun2022) Positive, notes: Nasal Swab. Therapeutic measures were not taken as a result of oropharyngeal pain, fatigue, malaise. No follow-up attempts are possible. No further information is expected.
5 days of bloody stool - 13, 14, 15, 16 of Dec and 18. Soreness or pain abdomen.
Headache, Myalgia, bicep/shoulder soreness, pectoral/thoracic pain Narrative:  Woke up with a severe headache, felt hungover, pain on pectoral/thoracic side and underarm feeling like she got punched or hit by a car on the same side she received her vaccine, painful to lift her arm above 90 degrees, feels very fatigued wanting to sleep all day, mental fog, not feeling as sharp, feels really run down. States her chronic arthritis could be exacerbating her symptoms. Taking Tylenol OTC.
1246: After receiving Covid vaccine, pt stood to leave after 15 mins and felt "disoriented" 1248: BP 128/77 HR 77 SpO2 96%  1250: Water given 1254: Stood up again, feeling better 1255: Walked home
he had his COVID 19 booster, after which he had reported emesis but otherwise felt in his usual state of health.   The today of admission, he recalls being en route to dialysis, and then having a lapse in recall and waking up at Hospital. According to admitting provider documentation, he had fallen asleep during HD and when he awoke he was alert and oriented to person only and was having difficulty following instructions.   On arrival to the hospital (1 day after vaccination) he has had a tmax 100.4 F. Blood cultures with no growth. Given cefepime and vancomycin but these were stopped after no blood culture. At time of eval on arrival, he seemed to have unconcerning mentation.
This spontaneous report has been received from a pharmacist via company representative referring to a patient of unknown age and gender. In about 2011 (reported as "more than 5 years ago"), the patient was vaccinated with a dose of ZOSTAVAX (strength, route, lot# and expiration date were not reported). On an unknown date the patient received a second dose of ZOSTAVAX (strength, route, lot# and expiration date were not reported). No adverse event was reported. Additional information has been requested.
symptoms of numbness, abnormal balance, loss of memory shortly after receiving vaccine.  I was admitted to hospital and underwent MRI and Lumbar puncture which determined there were abnormal findings suggestive of nerve damage. I was given IV high does steroids for 5 days.
This spontaneous report was received from a registered nurse via medical assistant and refers to a 13-month-old male patient. The patient's pertinent medical history, concurrent conditions, concomitant medications, past drugs and drug allergies were not reported. On 14-SEP-2017, the patient was vaccinated with improperly stored M-M-R II (lot # M034387; expiry date: 19-JUL-2018) (dosing details were not provided) for prophylaxis. Temperature excursion details of the vaccine were not provided. This is one of the several reports received from the same source. Sender's Comments: US-009507513-1709USA008861: US-009507513-1710USA013424: US-009507513-1710USA013470: US-009507513-1710USA013465: US-009507513-1710USA013440: US-009507513-1710USA013468: US-009507513-1710USA013442: US-009507513-1710USA013445: US-009507513-1710USA013460: US-009507513-1710USA013463: US-009507513-1710USA013464: US-009507513-1710USA013438: US-009507513-1710USA013439: US-009507513-1710USA013450: US-009507513-1710USA013430: US-009507513-1710USA013469: US-009507513-1710USA013467: US-009507513-1710USA013435: US-009507513-1710USA013434: US-009507513-1710USA013432: US-009507513-1710USA013428: US-009507513-1710USA013437: US-009507513-1710USA013441: US-009507513-1710USA013443: US-009507513-1710USA013444: US-009507513-1710USA013446: US-009507513-1710USA013447: US-009507513-1710USA013448: US-009507513-1710USA013436: US-009507513-1710USA013449: US-009507513-1710USA013451: US-009507513-1710USA013452: US-009507513-1710USA013454: US-009507513-1710USA013455: US-009507513-1710USA013456: US-009507513-1710USA013457: US-009507513-1710USA013458: US-009507513-1710USA013459: US-009507513-1710USA013461: US-009507513-1710USA013462: US-009507513-1710USA013466: US-009507513-1710USA013427: US-009507513-1710USA013471: US-009507513-1710USA013472: US-009507513-1710USA013473: US-009507513-1710USA013474: US-009507513-1710USA013475: US-009507513-1710USA013476: US-009507513-1710USA013425: US-009507513-1710USA013433: US-009507513-1710USA013423: US-009507513-1710USA013040: US-009507513-1710USA013426: US-009507513-1710USA013429: US-009507513-1710USA013431: US-009507513-1709USA008666: Original Case: 1709USA008666; US-009507513-1710USA014650: Original Case: 1710USA014649; US-009507513-1710USA014651: Original Case: 1710USA014649; US-009507513-1710USA014649Original Case: 1710USA014649.
Extreme bloating and gas accompanied with abdominal pain. Onset was around 6 hours after administration of vaccine. Pain became extreme and unbearable after 10 hours. After 12 hours, patient took 400 mg ibuprofen and the pain subsided but stomach and gastrointestinal tract is still bloated. Unknown if pain will return of if bloating will subside at the time of report.
12 hours after receiving the vaccine, I developed severe body aches, including my right knee almost unable to move/walk. I spiked a fever up to 101.8, chills with shivering/tremors, and a headache. Over 24 hours later, I am still experiencing significant body/joint aches. I also have developed a metallic taste in my mouth and anything I eat or drink tastes metallic. I have had chest pains and severe upper left and middle back pain.
This spontaneous report as received from a registered nurse refers to herself, a female patient of unknown age. Patient's pertinent medical history, concurrent condition and concomitant medication were not reported. No drug reactions/ allergies were reported. On an unknown date in 2017, a newborn patient was being vaccinated with RECOMBIVAX HB (lot# begins with "N00" and expiry date 08-NOV-2019) by the nurse for prophylaxis. When the dose of RECOMBIVAX HB was being administered to the newborn patient, the syringe separated from the needle and a small amount of the vaccine solution squirted in her eye (Occupational exposure while administering product). The vaccine dose was aspirated from a vial into an administration syringe and the needle was not firmly attached (product use issue). The nurse did not experience any adverse event. No PQC was involved. This report is cross linked with case#1706USA001456, due to the same reporter source. Additional information has been requested.; Sender's Comments: US-009507513-1706USA001456:
This spontaneous report as received from a physician refers to an unspecified number of patients of unknown age and gender. An unspecified number of doses of improperly stored vaccines: RECOMBIVAX HB (lot number and expiration date not provided), VAQTA (lot number and expiration date not provided) and GARDASIL (lot number and expiration date not provided) were exposed to temperatures as low as -2 Celsius for periods of approximately 0.5 hour might have been administered to an unspecified number of unspecified patients on unspecified dates. Additional information has been requested.
Parsonage Turner Syndrome treated steroids anti inflammatories and pain medication. Treatment was Physical therapy and Occupational therapy.  Outcome is pain and loss of full use of affected side, which is the right arm and hand
Arm soreness at site of injection appeared within 15 minutes, and has not subsided in 4 days.
Received vaccine past its 30-days Exp date Vaccines went into 2-8 C thaw state on or about 24-Dec-2021; Vaccine went into 2-8 Celsius thaw state on or about 24-Dec-2021 and administered on 'vaccine administration date; This spontaneous case was reported by an other health care professional and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Vaccine went into 2-8 Celsius thaw state on or about 24-Dec-2021 and administered on 'vaccine administration date) and PRODUCT STORAGE ERROR (Received vaccine past its 30-days Exp date Vaccines went into 2-8 C thaw state on or about 24-Dec-2021) in a 35-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 066H21A) for COVID-19 vaccination.     No Medical History information was reported.    On 05-Feb-2022 at 11:03 AM, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) .25 milliliter. On 05-Feb-2022 at 11:03 AM,  after starting mRNA-1273 (Moderna COVID-19 Vaccine), the patient experienced EXPIRED PRODUCT ADMINISTERED (Vaccine went into 2-8 Celsius thaw state on or about 24-Dec-2021 and administered on 'vaccine administration date). On an unknown date, the patient experienced PRODUCT STORAGE ERROR (Received vaccine past its 30-days Exp date Vaccines went into 2-8 C thaw state on or about 24-Dec-2021). At the time of the report, EXPIRED PRODUCT ADMINISTERED (Vaccine went into 2-8 Celsius thaw state on or about 24-Dec-2021 and administered on 'vaccine administration date) and PRODUCT STORAGE ERROR (Received vaccine past its 30-days Exp date Vaccines went into 2-8 C thaw state on or about 24-Dec-2021) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Concomitant medications were not reported. Treatment information was not reported.
Intrauterine fetal demise diagnosed on 10/19/21 when patient was 25 weeks and 5 day by an estimated delivery date of 1/27/22. She measured out to be 22 weeks 4 days by ultrasound. She was induced and delivered 10/20/21, with blood clot at placenta suggestive of placental abruption.
Patients says she experienced small bump at site of injection. She says bump was red irritated expanded to "grape size bump" 2 days later. She seeked medical treatment with local physician.
Pt recvd 2 doses of Hep B vax on 13MAR91 & 15APR91 approx 2 to 3 wks following 2nd worsening of arthritis;
Took the doses after every 2 days; Spontaneous report received on 23DEC2019.  A nurse reported that a female consumer "took the doses after every 2 days" (PT: Inappropriate schedule of product administration), while being on oral Vivotif for typhoid fever prophylaxis. The consumer took the four doses of Vivotif on 12SEP2019, 15SEP2019, 18SEP2019 and 21SEP2019. Action taken with Vivotif with respect to the reported event was not applicable. The outcome of the reported event was unknown.  Company Comment: A consumer took Vivotif doses after every 2 days (Inappropriate schedule of vaccine administered). The causality of the event is assessed as not related to Vivotif due to the nature of the event.; Sender's Comments: A consumer took Vivotif doses after every 2 days (Inappropriate schedule of vaccine administered). The causality of the event is assessed as not related to Vivotif due to the nature of the event.
I got the vaccine the day I was supposed to start my period. Its been almost a week with no period and very irregular and light spotting. This has never happened to me before, and there were no changes in stress or diet. I have not gotten my period.
tested positive after 1st dose; tested positive after 1st dose; This is a spontaneous report from a contactable Nurse. This nurse reported similar events for 2 patients. This is the second of two reports.   This Nurse reported for a 65-year-old female patient (Mother) received 1st dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE) on 22Dec2020 at single dose for covid-19 immunization. There was no medical history and no concomitant medications. Mother received 1st dose on 22Dec2020, tested positive for covid-19 infection after 1st dose. Outcome of the event was unknown.  Information on the lot/batch number has been requested.; Sender's Comments: Based on available information, a possible contributory role of the subject product, BNT162B2 vaccine, cannot be excluded for the reported events of Covid-19 virus test positive and suspected LOE  due to temporal relationship.   There is limited information provided in this report.  Additional information is needed to better assess the case, including complete medical history, diagnostics, counteractive treatment measures and concomitant medications.  This case will be reassessed once additional information is available.  The impact of this report on the benefit/risk profile of the Pfizer product is evaluated as part of Pfizer procedures for safety evaluation, including the review and analysis of aggregate data for adverse events. Any safety concern identified as part of this review, as well as any appropriate action in response, will be promptly notified to Regulatory Authorities, Ethics Committees and Investigators, as appropriate,Linked Report(s) : US-PFIZER INC-2021015122 same reporter/drug/AE, different patient.
Shortness of breath, chest pain/pressure, severe chills & uncontrollable shaking, Temp 36.2